

BLAU FARMACÊUTICA S.A.

Publicly Held Corporation

CNPJ/ME 58.430.828/0001-60

NIRE 35.300.416.406

CVM Code 2462-7

MATERIAL FACT**Blau signed a contract for the acquisition of Bergamo, from Amgen –
relevant company in the biotechnology sector**

BLAU FARMACÊUTICA S.A. (Ticker: BLAU3; “Blau” or “Company”), publicly-held company operating in the biotechnology sector, in compliance with the provisions of CVM Resolution No. 44, of August 23, 2021, as amended, hereby informs its shareholders and the market in general that, on this date, was completed the signing process of the Purchase Agreement with Amgen Group for the acquisition of 100% of the shares of Laboratório Químico Farmacêutico Bergamo Ltda (“Bergamo”) (“Transaction”), as approved at the Company’s Board of Directors meeting held on October 25, 2022. Amgen Brazil will continue its operations and serve its patients in the country.

With completion of the Transaction, Blau will increase its offer of Oncology products, with an important expansion in its production capacity in lyophilized, and will also add new products to the Company’s portfolio in the Oncology and Biological lines. Bergamo’s specialized commercial and marketing team is also another important asset for Blau, which brings a differentiating *go-to-market* model.

Founded in 1946, Bergamo facility is located in Taboão da Serra, close to São Paulo city and, in 2011, was acquired by Amgen. In 2021, it recorded Net Revenue of approximately BRL 185 million ¹ and produced around 2.2 million units of products. Currently, Bergamo has a portfolio of 190 products and around 190 employees.

Within the scope of the Transaction and after its completion, Blau will invest approximately USD 28 million for 100% of the share capital of Bergamo.

The completion of the Transaction is subject to the approvals of competent agencies and the fulfillment of precedent conditions. Blau will keep its shareholders and the market informed of relevant updates related to the Transaction.

Cotia, October 31st, 2022**Douglas Rodrigues**

CFO & IRO

About Blau Farmacêutica:

Blau is a leading pharmaceutical industry in the institutional segment and a pioneer in biotechnology, with an owned brands portfolio of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectiology, operating in different therapeutic classes

Blau has a continental footprint, present in 7 countries in Latin American – Brazil, Argentina, Colombia, Chile, Ecuador, Peru, Uruguay – and the United States, and has a modern pharmaceutical industrial complex in Brazil, composed of five industrial facilities, with state-of-the-art technology, dedicated to the production of biological and synthetic products.

¹ In audit process.